Edition:
United States

Evoke Pharma Inc (EVOK.OQ)

EVOK.OQ on NASDAQ Stock Exchange Capital Market

2.11USD
16 Feb 2018
Change (% chg)

$0.04 (+1.93%)
Prev Close
$2.07
Open
$2.10
Day's High
$2.13
Day's Low
$2.09
Volume
55,235
Avg. Vol
39,721
52-wk High
$4.09
52-wk Low
$2.07

Latest Key Developments (Source: Significant Developments)

Evoke Pharma Announces Discovery Of Sex-Based Pharmacokinetic Differences For Gimoti​
Thursday, 15 Feb 2018 07:30am EST 

Feb 15 (Reuters) - Evoke Pharma Inc ::EVOKE PHARMA INC - ‍EVOKE ANNOUNCES DISCOVERY OF SEX-BASED PHARMACOKINETIC DIFFERENCES FOR GIMOTI​.EVOKE PHARMA - ANALYSIS OF PK DATA BY SEX REVEALED STATISTICALLY SIGNIFICANT DIFFERENCES IN EXPOSURE BETWEEN WOMEN & MEN GIVEN SAME METOCLOPRAMIDE DOSE​.EVOKE PHARMA INC - ‍COMPANY HAS FILED NEW PATENT APPLICATIONS RELATED TO DISCOVERY​.EVOKE PHARMA INC - ‍COMPANY NOW EXPECTS TO FILE GIMOTI NDA IN Q2 OF 2018​.  Full Article

Evoke Pharma reports Q3 loss per share $0.34
Tuesday, 14 Nov 2017 04:05pm EST 

Nov 14 (Reuters) - Evoke Pharma Inc ::Evoke Pharma reports third quarter 2017 results and highlights.Q3 loss per share $0.34.Q3 earnings per share view $-0.20 -- Thomson Reuters I/B/E/S.  Full Article

Evoke Pharma signs commercial agreement with Thermo Fisher Scientific
Thursday, 9 Nov 2017 08:30am EST 

Nov 9 (Reuters) - Evoke Pharma Inc ::Signs commercial agreement with Thermo Fisher Scientific.Announced selection of Patheon division of Thermo Fisher Scientific as commercial manufacturing partner for Gimoti​.Under five-year agreement, Thermo Fisher will manufacture Gimoti for Evoke's potential commercial efforts​.  Full Article

Evoke Pharma reports positive topline results from comparative exposure pharmacokinetic study for gimoti
Monday, 23 Oct 2017 07:30am EDT 

Oct 23 (Reuters) - Evoke Pharma Inc ::Evoke Pharma announces positive topline results from comparative exposure pharmacokinetic study for gimoti™.Evoke Pharma- co will submit a 505(b)(2) NDA with a selected gimoti dose to the U.S. FDA in Q1 of 2018​.Evoke Pharma Inc- ‍relative to safety, all gimoti doses were well‑tolerated.  Full Article

Evoke Pharma reports Q2 loss per share $0.11
Monday, 14 Aug 2017 04:05pm EDT 

Aug 14 (Reuters) - Evoke Pharma Inc -:Evoke Pharma reports second quarter 2017 results and highlights.Q2 loss per share $0.11.Q2 earnings per share view $-0.15 -- Thomson Reuters I/B/E/S.  Full Article

Evoke pharma inc initiates comparative exposure Pharmacokinetic Study for Gimoti
Monday, 14 Aug 2017 08:30am EDT 

Aug 14 (Reuters) - Evoke Pharma Inc :Evoke Pharma Inc - ‍initiation of its comparative exposure Pharmacokinetic trial for Gimoti​.Evoke Pharma - ‍expects to complete analysis of trial data, announce results in Q4 2017, followed by potential nda submission in late 2017 or early 2018​.  Full Article

Evoke Pharma enters agreement with Rho to submit NDA for Gimoti
Wednesday, 31 May 2017 08:30am EDT 

May 31 (Reuters) - Evoke Pharma Inc :Evoke Pharma enters agreement with Rho to submit NDA for Gimoti.Evoke Pharma Inc - entered into agreement with Rho Inc for submission of its planned new drug application for Gimoti.Evoke Pharma says remain on track to initiate and complete our PK study in second half of this year with our NDA submission by late 2017 or early 2018.  Full Article

Evoke Pharma Q1 loss per share $0.37
Monday, 15 May 2017 04:05pm EDT 

May 15 (Reuters) - Evoke Pharma Inc :Evoke Pharma reports first quarter 2017 results.Q1 loss per share $0.37.Q1 earnings per share view $-0.16 -- Thomson Reuters I/B/E/S.  Full Article

Evoke Pharma presents Gimoti efficacy and safety data from phase 3 trial
Wednesday, 10 May 2017 08:30am EDT 

May 10 (Reuters) - Evoke Pharma Inc : :Evoke Pharma presents Gimoti efficacy and safety data from phase 3 trial as late breaker at digestive disease week 2017.Says safety data from phase 3 trial were consistent with favorable results from previous gimoti studies.Evoke Pharma - based on recent fda discussions, these data are anticipated to be submitted as part of a new drug application for Gimoti.Says trial data was not statistically significant in itt group.Evoke Pharma - patients, which 51pct enrolled in study, responded clinically and statistically significantly better to gimoti than placebo.  Full Article

Evoke Pharma announces collaboration with Spaulding Clinical Research
Tuesday, 18 Apr 2017 08:30am EDT 

April 18 (Reuters) - Evoke Pharma Inc ::Evoke Pharma Inc- announces collaboration with Spaulding Clinical Research for Gimoti comparative exposure pharmacokinetic trial.To complete PK trial in second half of 2017 with NDA submission for Gimoti to follow in late 2017 or early 2018.  Full Article

BRIEF-‍Mr Green Acquires Evoke Gaming Including Redbet​

* ‍PURCHASE PRICE OF EUR 7 MILLION IN CASH; AN ADDITIONAL PURCHASE PRICE OF EUR 1.5 MILLION MAY BE PAYABLE IF CERTAIN CONDITIONS ARE MET​